Atrás
Rango del Día
$22.30
$26.00
Rango de 52 Semanas
$22.30
$28.12
Volumen
2
Promedio 50D / 200D
$26.04
/
$26.36
Cierre Anterior
$26.00
Historial de Precios
Tendencias Financieras
Comparación con Pares
vs mediana del sector Healthcare (626 pares)
| Métrica | Acción | Mediana del Sector |
|---|---|---|
| P/E | 0.1 | 0.4 |
| P/B | 0.0 | 2.9 |
| ROE % | 9.4 | 3.8 |
| Net Margin % | 14.8 | 3.9 |
| Rev Growth 5Y % | 5.8 | 10.0 |
| D/E | 0.0 | 0.2 |
Precio Objetivo de Analistas
No hay cobertura de analistas disponible
Estimaciones de Ganancias
| Período | EPS Est. | Ingresos Est. | Analistas |
|---|---|---|---|
| FY2030 |
$79.80
$72.49 – $85.09
|
71 B | 1 |
| FY2029 |
$66.80
$60.68 – $71.23
|
73 B | 1 |
| FY2028 |
$39.17
$35.58 – $41.77
|
80 B | 1 |
Puntos Clave
Revenue grew 5.82% annually over 5 years — modest growth
Earnings grew 73.77% over the past year
Debt/Equity of 0.03 — conservative balance sheet
Generating 25.39B in free cash flow
P/E of 0.07 — trading at a low valuation
PEG of 0.15 suggests growth is underpriced
Crecimiento
Revenue Growth (5Y)
5.82%
Revenue (1Y)30.52%
Earnings (1Y)73.77%
FCF Growth (3Y)89.81%
Calidad
Return on Equity
9.41%
ROIC10.08%
Net Margin14.83%
Op. Margin22.37%
Seguridad
Debt / Equity
0.03
Current Ratio3.67
Interest Coverage751.21
Valoración
P/E Ratio
0.07
P/B Ratio0.01
EV/EBITDA-2.34
Dividend Yield0.05%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 30.52% | Revenue Growth (3Y) | 13.51% |
| Earnings Growth (1Y) | 73.77% | Earnings Growth (3Y) | 60.11% |
| Revenue Growth (5Y) | 5.82% | Earnings Growth (5Y) | 0.99% |
| Profitability | |||
| Revenue (TTM) | 94.04B | Net Income (TTM) | 13.95B |
| ROE | 9.41% | ROA | 7.32% |
| Gross Margin | 62.24% | Operating Margin | 22.37% |
| Net Margin | 14.83% | Free Cash Flow (TTM) | 25.39B |
| ROIC | 10.08% | FCF Growth (3Y) | 89.81% |
| Safety | |||
| Debt / Equity | 0.03 | Current Ratio | 3.67 |
| Interest Coverage | 751.21 | Dividend Yield | 0.05% |
| Valuation | |||
| P/E Ratio | 0.07 | P/B Ratio | 0.01 |
| P/S Ratio | 0.01 | PEG Ratio | 0.15 |
| EV/EBITDA | -2.34 | Dividend Yield | 0.05% |
| Market Cap | 984.58M | Enterprise Value | -49.26B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 94.04B | 72.04B | 72.98B | 76.03B | 74.98B |
| Net Income | 13.95B | 8.03B | 5.44B | 9.55B | 13.41B |
| EPS (Diluted) | 365.42 | 212.66 | 144.79 | 251.44 | 347.37 |
| Gross Profit | 58.53B | 38.54B | 39.56B | 41.58B | 40.91B |
| Operating Income | 21.03B | 9.51B | 8.00B | 17.06B | 17.79B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 190.42B | 171.62B | 166.33B | 165.18B | 163.33B |
| Total Liabilities | 37.79B | 27.87B | 29.49B | 26.86B | 27.08B |
| Shareholders' Equity | 152.63B | 143.76B | 136.26B | 137.75B | 136.26B |
| Total Debt | 3.85B | 3.85B | 3.85B | 3.85B | 3.85B |
| Cash & Equivalents | 54.09B | 50.63B | 59.56B | 61.03B | 63.71B |
| Current Assets | 111.38B | 106.97B | 109.90B | 110.61B | 113.66B |
| Current Liabilities | 30.35B | 19.02B | 20.84B | 19.05B | 21.28B |
Puntuaciones de Estrategias
This stock passed the criteria for 4 strategies
Score = fit strength (0–100)
Rank = position among all matches
Actividad Reciente
Entró
Cash Flow Compounder
Mar 24, 2026
Entró
Deep Value Investing (Seth Klarman)
Mar 24, 2026
Entró
Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026
Entró
Defensive Investing (Benjamin Graham)
Mar 24, 2026